Top AI Companies (7,018)

Strong Revenue Growth: Company disclosures cite 40% growth in 2023 and 38% subscription revenue growth in 2024, with record quarters and continued momentum into 2026. Evidence suggests recurring-revenue scaling is supported by new customer additions and expansions.

Innovation-Driven Growth: Rapid uptake of AI offerings (e.g., Pricefx Agents and Copilot) is described, including dozens of enterprise deals within months and deployments at 50 companies. Feedback suggests these innovations are monetizing quickly and creating new growth vectors.

Customer Loyalty & Retention: Retention above 97% in 2024 and an installed base of 190+ customers across 27 countries point to durable relationships and stickiness. Evidence suggests expansions within existing customers are contributing alongside net-new logos.

Strong Revenue Growth: Company disclosures indicate very strong year-over-year revenue expansion in 2023 with continued gains into 2024 alongside client growth. Investor communications also highlight a significant valuation step-up between the 2023 and 2024 financing rounds, reinforcing momentum.

Market Expansion: Expansion efforts are evident in a rapid international buildout, with notable growth across EMEA and new entries in APAC, adding many new firms and operating across numerous countries. This points to widening geographic reach and ongoing customer acquisition.

Investor Backing & Capital Strength: Capital support appears strong, including a sizable Series C led by a major institutional investor and a definitive agreement to be acquired by Bloomberg. These events suggest external validation and resources to sustain scaling.

Investor Backing & Capital Strength: Funding progression includes a reported Series A in 2023 and total capital in the mid‑teens of millions, indicating resources to scale operations and product. Named institutional investors and multiple rounds point to continued capacity to support growth initiatives.

Market Expansion: Positioning has broadened from forestry robotics into AI‑powered field operations for utilities, including vegetation management, asset inspection, construction, and disaster response. This shift suggests access to larger, higher‑value commercial segments.

Product Line Growth: Activity logs cite next‑generation backpack and vehicle hardware shipments, faster data processing, expanded species identification, and a desktop review application. These updates indicate ongoing investment in capabilities aligned to real‑world utility workflows.

Strong Revenue Growth: Annualized revenue increased from $720M in March 2025 to $1.3B by March 2026, with ARR surpassing $1B in late 2025 and continuing upward. This trajectory points to sustained top-line momentum across the period cited.

Market Expansion: Geographic reach broadened with new regulated entries across multiple regions, alongside plans to deploy over $1B in the U.S. and substantial investment in Europe. Regional performance in the Americas and EMEA also advanced meaningfully, indicating traction beyond APAC.

Investor Backing & Capital Strength: Valuation rose from $6.2B (May 2025) to $11B (June 2026) through successive large funding rounds. Independent reporting corroborated the latest financing, signaling strong capital access and external confidence.

Market Expansion: The platform’s footprint expanded from 400 participating sites in 2022 to 6,000+ sites by 2026, with presence across 50+ countries and 25+ sponsors. Evidence indicates marketplace adoption more than doubled in 2023 and activity surpassed 100 trials by 2024.

Product Line Growth: The offering broadened from a marketplace into AI-powered patient pre-screening and integrated workflows, with reported operational time savings and enrollment improvements in case studies. Subsequent integrations with CRIO, RealTime eClinical, and eClinPro signal continued platform expansion.

Strategic Partnerships: Relationships include major pharmaceutical organizations (e.g., 16 of the top 30 in 2024 and now 25+ sponsors) and ecosystem deals such as RealTime eClinical (50+ networks representing 2,000+ sites) plus CRIO/eClinPro integrations. These ties appear to extend distribution and enrich data used for site selection and enrollment.

Market Expansion: Granted is extending beyond direct-to-consumer into institutional channels, launching a North Texas educator program initially covering 5,000+ Mesquite ISD employees with additional districts expected. A September 2026 rollout of Clear the Bill further signals targeted regional program expansion.

Strategic Partnerships: Collaborations with First Financial Group of America and StretchDollar are broadening access through employer and benefits distribution. These partnerships are described as recent commercial expansions and the company’s first school‑district collaboration.

Investor Backing & Capital Strength: The company secured approximately $16.25M–$16.3M in a 2024 Series A/financing, cited by multiple industry sources. This level of backing indicates meaningful investor support for continued development and scaling.

Investor Backing & Capital Strength: Recent financings include a $55M Series B led by Insight Partners and a prior $15M Series A, bringing total reported funding to roughly $77M. These capital events coincide with visible signals like active hiring and continued platform build-out.

Strong Revenue Growth: Growth is repeatedly described as 5x year-over-year since the Series A, alongside a 5x increase in valuation. Customer adoption reportedly expanded to 250+ CPG brands with $30B+ in retail sales planning flowing through the platform.

Product Line Growth: The offering has broadened from cash application and deductions into trade promotion management, sales forecasting, demand/supply planning, and analytics. Additions such as AI contract reading, auto‑disputes, and the Muffin Data acquisition indicate ongoing capability expansion.

Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.

Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.

Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.

Strong Hiring & Retention: Headcount is reported to have expanded by 32 in 2025, and current listings show multiple open roles across engineering, data, security, operations, and customer success. LinkedIn also shows roughly 85 employees, reinforcing sustained organizational growth.

Product Line Growth: Regulatory and product momentum includes FDA clearance of the eVO2peak Module in December 2025 and a portfolio the company describes as 12 cardiovascular digital biomarkers (8 FDA-cleared, 4 clinically validated). This indicates an expanding set of regulated and validated offerings on its platform.

Strategic Partnerships: Integration into Kardigan following the 2025 acquisition connects the platform to an active cardiovascular drug-development pipeline and clinical programs. SEC disclosures outline Prolaio-related patient and revenue milestones and describe deployment in Kardigan’s trials.

Profitability: Net income turned from -$27.9M in FY2025 to +$37.9M in FY2026, and adjusted EBITDA rose from $67.0M to $107.3M with margin expansion. Profitability continued into FY2027 with strong quarterly EBITDA performance.

Cost & Operational Efficiency: Operating discipline, restructuring, and reduced expenses are credited with materially improving margins and earnings despite muted top-line trends. The business has shifted from loss-making expansion to efficiency and margin expansion.

Future-Ready Strategy: Product investments and positioning around AI/agentic marketing (e.g., Scout, Corvo AI) and targeted acquisitions (e.g., Hearsay) indicate a pivot toward AI-driven search visibility and regulated-industry use cases. This suggests preparation for evolving demand rather than reliance solely on legacy listings revenue.

Strong Revenue Growth: Revenue is described as rising from about $3.5M in 2021 to roughly $80M in 2024, with annual contract value also increasing substantially. Feedback suggests this momentum reflects rapid scaling of contracted business.

Profitability: The company is reported to have become profitable within three years and to have maintained profitability thereafter. This points to efficient scaling rather than reliance solely on external financing.

Market Expansion: Contracting progressed from prototypes to a DIU production vehicle with a $99M ceiling, followed by additional Air Force and OSD awards through 2025–26. The stated footprint grew to about 125 deployments across every service branch and combatant command.

Strong Revenue Growth: Revenue appears to be increasing over time, with evidence of substantial growth in 2022 and continued year-over-year expansion into early 2023, even as the pace moderates. Feedback suggests the business is still scaling toward a larger revenue base while transitioning to a mature growth profile.

Profitability: Independent credit commentary highlights improved profitability and a deliberate shift toward a profit-focused operating model. Feedback suggests efficiency gains and margin improvement are becoming central to the company’s stability and growth trajectory.

Innovation-Driven Growth: Ongoing AI platform investment, rising adoption of AI capabilities, and product expansion including acquisitions are cited as current growth engines. Feedback suggests these initiatives are supporting continued operational and market expansion.

Product Line Growth: Growth in medicines such as Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec/Vydura and oncology biosimilars more than offset part of the COVID-related decline in the first half of 2026. Launched and acquired products also delivered strong double‑digit operational gains in Q2 2026.

Resilient & Sustainable Growth: Underlying revenue excluding COVID products advanced at a mid‑single‑digit pace in 2025 and the first half of 2026, while total revenue returned to modest year‑over‑year growth in early 2026. Management raised the midpoint of 2026 revenue guidance, signaling improving momentum beneath headline totals.

Future-Ready Strategy: Heavy investment in a broad late‑stage pipeline and plans for numerous pivotal study starts in 2026 support longer‑term growth. Continued business development and integration of acquired assets are positioned to offset COVID normalization and loss‑of‑exclusivity pressures over time.

Investor Backing & Capital Strength: Funding advanced to a $50M Series B in June 2025, with total capital reported around $72–73.5M, signaling strong investor support. The step-up from the 2022 $17M Series A is described as enabling continued development and international expansion.

Product Line Growth: The platform has expanded from AI-powered consumer intelligence into trend forecasting, product innovation, marketing activation, foodservice sales, and AI agents, and is now positioned as an “agentic intelligence system” for F&B. Claims of a markedly larger data footprint further indicate sustained product development.

Market Expansion: Capital has been used to scale across North America, Europe, and APAC, following earlier moves into markets including Canada, Australia, Germany, France, and India. Company materials also point to broad enterprise penetration among major F&B brands and a growing set of customer stories.

Investor Backing & Capital Strength: Investor backing is highlighted by seed and Series A rounds led by Accel and participation from notable angels, bringing total funding to roughly $19.7M. Feedback suggests this capital has supported team expansion and product development.

Market Expansion: Customer additions include fast-growing tech companies like Mintlify, Equals, and Braintrust, with accounts noting switches from legacy systems such as QuickBooks and NetSuite. Feedback suggests the company is extending its presence within the AI-native accounting niche for startups.

Innovation-Driven Growth: The platform combines an AI-native general ledger with managed services, continuous reconciliation, and tools like Prism for real-time financial exploration. Feedback suggests this differentiated product approach underpins traction among modern software companies.

Market Expansion: The client base appears to have grown from 800+ hospitals in 2021 to more than 1,000 by the October 2025 acquisition, indicating broader market reach. The buyer also stated the deal would expand its total addressable market by more than 15%.

Product Line Growth: Offerings broadened through acquisitions of Artifact Health and ChartWise and launches such as AwareUM and pre-bill capabilities. This reflects expansion from core CDI into utilization management and adjacent mid–revenue-cycle workflows.

Investor Backing & Capital Strength: The company reached a valuation of about $1 billion in 2021 and was acquired for approximately $1.25 billion in 2025. The acquirer characterized the business as a highly recurring subscription model expected to be accretive to its financial profile.

Market Expansion: Geographic expansion is evident through the Doctus acquisition and the establishment of a Medellín development hub, extending operations beyond the Chicago base. This move expanded global reach and delivery capacity.

Product Line Growth: Offerings now span AI consulting and solutions alongside proprietary products such as Tixie, ACE Commerce, and SmartSeat. Recent platform modernizations and AI-focused client work indicate continued portfolio development.

Strong Hiring & Retention: Headcount signals point upward and careers pages across the U.S. and Colombia indicate ongoing recruitment in strategy, design, and technology. Employer recognition such as Best and Brightest listings supports a picture of organizational stability.

Strong Hiring & Retention: Headcount is described as having grown to about 25 people, with active hiring across product, engineering, and AI sales. A new West Loop Chicago office underscores ongoing organizational build-out.

Product Line Growth: The platform launched publicly in February 2026 and supports multiple operational use cases with 1,300+ integrations. Materials highlight ready-to-run agents spanning sales, support, operations, recruiting, and more.

Market Expansion: Public pages cite a new Chicago office and indicate customers can deploy agents across business workflows, with a visible “Trusted By” section and a named user like CoinFlip. These signals point to movement from development into commercial deployment.

Investor Backing & Capital Strength: A $15M commitment from Erie Street Growth Partners in 2024 was explicitly aimed at scaling operations and “supercharging” growth, indicating strong capital support. Independent coverage confirms the funding and positions the company as actively expanding its AI-transformation platform.

Strong Hiring & Retention: Signals point to expansion to 100+ forward-deployable experts, with LinkedIn showing the 51–200 employee band and company materials citing a broad multidisciplinary team. Leadership additions and an acquisition that increased headcount further indicate active workforce scaling.

Market Expansion: The Dhauz acquisition extended the footprint across North America, Europe, and South America. Offerings now span AI transformation, agentic workflows, governance, workforce adoption, and multiple business functions, reflecting a broader commercial presence.

Strong Revenue Growth: Trading revenue is described as reaching record levels in 2025 and again in 2026, including very large quarterly hauls. Reporting indicates momentum has accelerated alongside expansion across asset classes and regions.

Profitability: Net income is portrayed as exceptionally strong in recent quarters, signaling substantial earnings power alongside top-line gains. Observations point to operating leverage from a scalable, technology-heavy model.

Investor Backing & Capital Strength: A revised Positive outlook from a major rating agency and commentary on a growing capital base suggest a strengthening financial footing. This is reinforced by continued investment capacity, including multi-year AI infrastructure partnerships.